The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- Japan Lung Cancer Society Seeks Early 1st-Line Nod for Keytruda
October 26, 2016
- Saitama Medical Univ. Develops Jointly with Daiichi Sankyo New Antibody with Potential Application in Treatment of FOP
October 26, 2016
- 6 Drug Makers to Participate in “Drug Redirection Program” for Compounds in Development Limbo: Univ. of Tokyo’s Initiative
October 18, 2016
- Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
October 7, 2016
- Amendment to Personal Info Law Shouldn’t Stymie Epidemiology Studies: Doctors
September 27, 2016
- Japan Hypertension Society to Soon Report VART Paper Retraction in Publication
September 26, 2016
- Univ. of Tokyo to Launch Probe into 22 Scientific Papers after Data Manipulation Claims
September 23, 2016
- Japan, Korea NCCs to Collaborate in Personnel Exchanges, Joint Research
September 7, 2016
- JAMS Pres. Takaku, Global Scientists Call for HPV Vaccine Recommendation
August 30, 2016
- Japan Hypertension Society to Retract Diovan Paper on VART Study
August 16, 2016
- Japan Society Draws Up New Guidelines on Depression
August 16, 2016
- 3 Scientific Societies to Set Up HBOC Body to Build BRCA Gene Database
August 4, 2016
- Scientific Panel Fails to Reach Consensus on Withdrawal of Antiresorptive Agents Before Oral Invasive Surgery
July 27, 2016
- New Enuresis Treatment Guidelines Recommend Desmopressin as First-Line Pharmacotherapy: Japanese Society on Enuresis
July 26, 2016
- Regenerative Medicine Society to Introduce Treatment Compensation System in November
July 26, 2016
- Japanese Society of Nephrology Aims to Promote Development through “Surrogate Endpoints”; Hopes to Draft Guidelines in FY2017
July 22, 2016
- 1st Line Statins Likely to Be Recommended for Pediatric Familial Hypercholesterolemia
July 21, 2016
- New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
July 20, 2016
- Japan Oncology Society Warns of Privately Imported Opdivo, Yervoy
July 19, 2016
- JSGO Will Revise Guidelines to Recommend Bevacizumab in Treatment of Stage IVB/Relapsed Cervical Cancer
July 14, 2016
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…